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Background: In 2006, the first-line anti-malarial drug treatment in Tanzania was changed from
sulphadoxine-pyrimethamine (SP) to artemether-lumefantrine (ALu), an artemisinin-based combination (ACT), since
when the use of SP has been restricted for intermittent preventive treatment in pregnancy (IPTp). A number of
Plasmodium falciparum mutations are known to be associated with resistance to SP, but it is not known if the prevalence
of these mutations is increasing or decreasing under the conditions of reduced levels of SP use. This study reports on
the current SP resistant quintuple Pfdhfr-Pfdhps mutations in six regions of Tanzania.
Methods: Finger-prick blood on filter paper and rapid diagnostic test strips from P. falciparum-positive individuals of all
age groups attending health facilities in six regions of Tanzania between June 2010 and August 2011 were obtained.
Using chelex-100 extracted DNA, genotyping was done for mutations on codons 51, 59 and 108 of Pfdhfr and 437 and
540 of Pfdhps genes using PCR-RFLP technique.
Results: A total of 802 malaria-positive samples were screened and genotyped. The prevalence of Pfdhfr 51I, Pfdhps
437G and 540E varied between the regions (p < 0.001) whereas Pfdhfr 59R (FE 10.79, p = 0.225) and 108 N (FE 10.61,
p = 0.239) did not vary between the regions. The Pfdhfr triple mutant was above 84% and close to fixation levels in all
regions, whereas the Pfdhps double mutation ranged from 43.8 to 97% between the regions. The quintuple mutant
(IRNGE) was the most prevalent in all regions and it varied significantly from 37.5 to 90.2% (χ2 = 1.11, p <0.001).
Conclusions: There is evidence of persistent high levels of SP resistance markers in Tanzania with evidence of quintuple
mutations that are likely to become fixed in the population. This threatens the future of SP not only in IPTp programmes,
but as a combination drug for ACT. Continuous monitoring of SP-IPTp efficacy should be encouraged subsequent to
searching for alternative drugs for IPTp in East Africa.Background
Tanzania introduced sulphadoxine-pyrimethamne (SP)
as first-line treatment drug for uncomplicated malaria
in 2001, replacing chloroquine (CQ), which had been
the first-line since the 1970s [1]. Before it was declared
first-line, SP was already in use as second-line drug and
resistance had already developed [2,3]. This led to a
rapid spread of SP resistance and eventually SP was
replaced with the current artemisinin-based combin-
ational therapy (ACT) by the end of 2006 [4]. Due to* Correspondence: rekavishe@yahoo.com
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in the first trimester, SP has continued to be used in inter-
mittent preventive treatment of malaria in pregnancy
(IPTp) and infants (IPTi). For IPTp, two or more doses of
SP are administered after the first trimester at intervals of
at least one month apart. The importance of SP-IPTp in
prevention of malaria in pregnancy and the resulting out-
comes, such as low birth weight, abortion, premature
birth, perinatal death, and maternal mortality, have been
documented globally and WHO has continued to recom-
mend SP-IPTp use [5-8]. SP resistance has however
continued to rise and several studies have reported re-
duced protection of SP-IPT programmes in areas where
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http://www.malariajournal.com/content/13/1/152SP resistance is caused by mutation on two genes, the
dihydrofolate reductase (Pfdhfr) and the dihydropteroate
synthetase (Pfdhps) genes. Three Pfdhfr mutations: N51I,
C59R and S108N, referred to as the triple mutation, and
the Pfdhps mutations: A437G and G540E, referred to as
the double mutation, collectively form the quintuple
mutations [12,13]. An additional mutation on Pfdhps
581 has been associated with high level of SP resistance
and a strong predictor of SP-IPTp failure [14] and in
addition to the quintuple forms the sextuple mutation.
In East Africa SP resistance has reached over 90% and in
some places the prevalence of the quintuple mutation is
approaching fixation levels [15]. In Tanzania only two
studies in Igombe-Mwanza and Korogwe-Tanga have
documented the prevalence of quintuple mutation in
2008/2011 period. All other studies have used samples
collected before or during the transition from SP to
ACT in 2006. It is thus not clear whether SP resistance
is decreasing or increasing in the advent of its restricted
use. The current study set out to investigate the current
SP resistance based on quintuple mutations in Tanzania.
Methods
Samples collected through collaboration with ongoing
studies in six regions of mainland Tanzania between
June 2010 and August 2011 were used in this study. In
Coastal Region the sample involved pregnant women
attending the Kibiti health centre for intermittent pre-
ventive treatment of malaria. Sampling from all other
regions involved all age groups. Finger-prick blood
on filter paper (Whatman-3) or rapid diagnostic test kits
(Mwanza samples) from febrile patients attending various
health facilities in the respective regions were collected
after patients’ or children’s guardians had consented to the
use of their blood samples for malarial genetic studies.
The study sites included Mwanza (Misungwi district) and
Kagera (Muleba district) around Lake Victoria in the
north-western zone, Tanga (Bondo village) in the north-
eastern zone, Mtwara (Tandahimba and Mtwara-Urban)
and Coastal Region (Kibiti-Rufiji) in the south-eastern
zone, and Mbeya (Kyela and Rungwe districts) in the
south-western zone. The malaria-positive rapid diagnostic
test (RDT) strips or dried filter-paper blood spots were
stored in desiccant at room temperature. Malaria parasite
DNA was extracted using chelex-100 method as described
previously [16]. Genotyping for Pfdhps and Pfdhfr was
performed using PCR-RFLP methods described by others
[17,18]. In short, nested PCR were performed followed by
restriction digestion of the secondary products. For Pfdhfr
Tsp509I, XmnI and AluI were used for positions 51,
59 and 108 respectively whereas for Pfdhps 437 and
540 AvaII and FokI were used, respectively. For each
enzyme there were digestion control sites as previously
described [17] in addition positive controls were usedin each experiment. Digestion products were eluted on
2% agarose gel (Invitrogen, USA) stained with ethidium
bromide and visualized under UV light. All PCR reagents
and restriction endonucleases were purchased from New
England Biolabs (Ipswich, MA, USA). Primers were
purchased from Biolegio (Nijmegen, the Netherlands).
Prevalence was calculated as the percentage of wild
type or mutants out of the new total samples geno-
typed. Very few mixed infections were observed in this
study and were excluded from the analysis as it was
not possible to include them in haplotype analysis. The
study received ethical approval from the Kilimanjaro
Christian Medical University College Ethical Board sub-
sequent to the National Institute for Medical Research
Ethics approval obtained in the collaborating projects.
Results
A total of 802 P. falciparum positive blood samples were
screened and genotyped; 785, 787, 765, 762 and 752
were successfully genotyped for mutations at codons 51,
59, 108, 437 and 540 respectively; 707 (88%) of the 802
were successfully analyzed for the quintuple haplotypes.
At codons 51, 59, 108 and 437, 0.6, 1.4, 1.3 and 1.4% of
the genotyped samples had mixed genotypes. No mixed
genotypes were observed at codon 540. Since the per-
centages were low, samples with mixed genotypes were
excluded from haplotype calculation. Significant differ-
ences in prevalence of Pfdhfr 51I (FE 10.79, p < 0.001),
Pfdhps 437G (χ2 = 1.5, p < 0.001) and 540E (χ2 = 1.12,
p < 0.001) were observed between the regions. However,
the prevalence of Pfdhfr 59R and 108 N mutations was
not different between the regions (FE 10.79, p = 0.225
and FE 10.61, p = 0.239, respectively).
Pfdhfr mutations were the most prevalent (Figure 1)
with the triple mutant (IRN) ranging from 84.4 (Coastal)
to 96.6% (Tanga) compared to Pfdhps double mutant
(GE) which ranged from 43.8 to 97% (Table 1). Both the
triple mutant and the double mutants were statistically
different but when Coastal region was excluded the dis-
tribution of the IRN triple mutant was no longer differ-
ent (FE 2.75, p = 0.594). The wild type Pfdhfr (NCS) and
Pfdhps (AK) were detected at very low levels (0.1% and
5.1% respectively) (Table 1).
Six common quintuple haplotypes were observed from
the analysis (Table 2) with overall prevalence ranging
from 1.8 to 76.9% depicted in Figure 2. An additional 13
minor haplotypes with prevalence less than 1% were
grouped as “others” and constituted only 4.1% of the overall
haplotypes. These include NRNGK (0.6%), IRSAK (0.4%),
NCNGE (0.4%), NCNAK(0.3%), NCNGK (0.3%), NRNAE
(0.1%), IRSAE (0.1%), IRSGK (0.1%), ICNGE (1.1%),
NRNAK (0.1%), ICNGK (0.1%), NCSGE (0.1%) and ICNAE
(0.1%). The IRNGE haplotype (quintuple mutant) was the
most prevalent haplotype in all regions and it varied
Figure 1 Prevalence of Pfdhfr and Pfdhps mutations in Tanzania. X-axis represents the six regions sampled and y-axis presents percentage
prevalence calculated as total number of mutants or wild types per total number of samples per region.
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(Table 2). Tanga, Mbeya, Mwanza and Kagera regions had
the highest prevalence of the quintuple mutation compared
to Coastal and Mtwara regions (Table 2 and Figure 2).
Discussion
Selection for SP resistance markers in Tanzania has
remained high even after the replacement of SP for first-
line treatment of uncomplicated malaria in 2006. The
selection for individual Pfdhfr and Pfdhps mutations is
very high throughout Tanzania. Comparing individual
mutations, Pfdhfr 59R is already fixed in Mtwara region
while 108 N and Pfdhps 437 are fixed in Tanga (Bondo).
In Korogwe-Tanga, the 51I, 59R and 108 N were already
above 95% in 2006 [14] and in Mbeya-Matema, in 2005
the 51I, 59R, 108 N, 437G, and 540E were 93, 80, 97.7,
78.6 and 77.4%, respectively [19]. A similar increase was
observed in Mwanza Region. Between 2010 and 2011 the
prevalence of 51I, 59R, 108 N, 437G, and 540E in Igombe-
Mwanza was 75, 82.5, 94.8, 74, and 69.5%, respectively
which is comparable to the current findings [20].Table 1 Prevalence of Pfdhfr triple and Pfdhps double mutant
Pfdhfr n (%)
Regions IRN IRS ICN NRN NCN NCS
Coastal 81 (84.4) 5 (5.2) 0 (0) 3 (3.1) 7 (7.3) 0 (0)
Tanga 112 (96.6) 0 (0) 2 (1.7) 2 (1.7) 0 (0) 0 (0)
Mtwara 59 (92.2) 2 (3.1) 0 (0) 3 (4.7) 0 (0) 0 (0)
Mbeya 127 (96.2) 3 (2.3) 2 (1.5) 0 (0) 0 (0) 0 (0)
Mwanza 126 (96.2 2 (1.5) 2 (1.5) 0 (0) 0 (0) 1 (0.8)
Kagera 158 (94.0) 6 (3.6) 4 (2.4) 0 (0) 0 (0) 0 (0)
Total 663 (93.8) 18 (2.5) 10 (1.4) 8 (1.1) 7 (1.0) 1 (0.1)The wild type Pfdhfr haplotype NCS was reported at
1.9% in Tanga-Korogwe in the period 2008/2010 [21]
but in this study it was not detected, it was detected in
Mwanza at 0.8%. This indicates disappearance of the
wild type haplotypes as the mutants increase.
Furthermore, compared to studies conducted between
2006 and 2007 around the time when SP was withdrawn
as first line drug, the triple mutant (IRN) was 90 – 96.4%
in Tanga (Korogwe), 74% in Coastal (Rufiji) and Mtwara/
Lindi regions while in Mbeya (Matema) it was 82.6% in
2005 [19,22-24], thus there has been a continuous selec-
tion for the Pfdhfr triple mutants to date. Similarly, from
around 2006 the double mutant (GE) and the quintuple
respectively have continued to increase from 63 and 75%
in Tanga [14,22], and 81 and 64% in Mbeya [19] while the
GE increased from 57% in Lindi/Mtwara. There was no
statistical difference in the distribution of the IRN across
regions indicating homogeneity in SP selection pressure
throughout the country.
The Pfdhps double (GE) mutant varied between the
regions. While the prevalence was lower in Mtwaras in Tanzania
Pfdhps n (%)
Total GE GK AE AK Total
96 59 (61.5) 13 (13.5) 15 (15.6) 9 (9.4) 96
116 107 (92.2) 9 (7.8) 0 (0) 0 (0) 116
64 28 (43.8) 8 (12.5) 12 (18.8) 16 (25.0) 64
132 128 (97.0) 1 (0.8) 3 (2.3) 0 (0) 132
131 122 (93.1) 0 (0) 5 (3.8) 4 (3.1) 131
168 148 (88.1) 1 (0.6) 12 (7.1) 7 (4.2) 168
707 (100) 592 (83.7) 32 (4.5 47 (6.6) 36 (5.1) 707 (100)
Table 2 Prevalence of Pfdhfr-Pfdhps common haplotypes in six regions of Tanzania
Common quintuple haplotypes n (%) Total (N)
IRNGE NRNGE IRNGK IRSGE IRNAE IRNAK OTHER*
Regions Coastal 51 (53.7) 2 (2.1) 9 (9.5) 2 (2.1) 13 (13.7) 6 (6.3) 12 (12.6) 95
Tanga 96 (82.8) 9 (7.8) 9 (7.8) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.7) 116
Mtwara 24 (37.5) 4 (6.2) 6 (9.4) 0 (0.0) 12 (18.8) 13 (20.3) 5 (7.8) 64
Mbeya 119 (90.2) 5 (3.8) 0 (0.0) 3 (2.3) 3 (2.3) 0 (0.0) 2 (1.5) 132
Mwanza 115 (87.8) 2 (1.5) 0 (0.0) 2 (1.5) 5 (3.8) 2 (1.5) 5 (3.8) 131
Kagera 138 (82.1) 1 (0.6) 1 (0.6) 6 (3.6) 11 (6.5) 7 (4.2) 4 (2.4) 168
Total 543 (76.9) 23 (3.3) 25 (3.5) 13 (1.8) 44 (6.2) 29 (4.1) 29 (4.1) 707
*Other haplotypes include: NRNGK, IRSAK, NCNGE, NCNAK, NCNGK, NRNAE, IRSAE, IRSGK, ICNGE, NRNAK, ICNGK, NCSGE and ICNAE.
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Mbeya, Mwanza, Tanga and Kagera. This may be
accounted for by inter regional variations in the use of
SP especially during or before SP became first line
treatment drug. Before 2001 SP was second line drug
and CQ was the first line. During this time SP resist-
ance had already occurred. This contributed to a rapid
spread of resistance after SP was made first line in
2001. In 2005 Mbeya registered exceptionally highFigure 2 Prevalence of Pfdhfr-dhps common quintuple haplotypes inlevels of GE (81%) [19] and in the current study
Mbeya is the leading with highest levels of SP resist-
ance (Tables 1 and 2, Figure 1).
Six common quintuple haplotypes were observed.
The observed high levels of the quintuple mutation in
all regions derive from the high levels observed with
the triple and double mutations of Pfdhfr and Pfdhps.
7The low levels of double mutant (GE) in Coastal and
Mtwara regions resulted into low levels of the quintupleTanzania.
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to recent studies in other East African countries. In
western Kenya samples obtained from pregnant women
between 2008 and 2009 were found to harbour more
than 90% Pfdhps double mutant and more than 80%
quintuple mutation [25]. In Mozambique SP resistance
quintuple mutation was reported to be above 75% in 2008
while the triple mutation had reached 100% (fixation) [26].
These reports point to high SP resistance in the East
African region as opposed to the West African region
where SP resistance based on the quintuple mutation is
still low in most countries, thus SP-IPT is still effective
[27-29].
The prevalence of the quintuple mutation in the para-
site confers high level SP resistance. In East Africa high
levels of this haplotype are likely to compromise the
importance of SP-IPTp [30]. Several studies have shown
that although implementation of SP-IPTp does not pre-
vent malaria infection during pregnancy, especially in
the presence of high prevalence of SP-resistance markers
[14,31,32], there is a significant protection against severe
outcomes of pregnancy in malaria, such as low birth
weight, maternal and neonatal mortality, especially when
more than two doses of IPTp are administered [33]. This
led to WHO’s continued recommendation for SP-IPTp
at any level of quintuple mutations [34]. However,
continued SP-IPTp is likely to exacerbate the spread of
the highly resistant Pfdhps mutation 581 previously
reported to associate with IPTp failure in East Africa
[14,25]. Thus, aside from the WHO recommended > two
doses of SP-IPTp, the high prevalence of SP resistance
markers observed in Tanzania and elsewhere in East
Africa calls for careful and continuous evaluation of
SP-IPTp efficacy and on the usefulness of SP in artemi-
sinin combinations. There is a need to screen pregnant
mothers for malaria parasites even when they are
already on IPTp in order to identify early treatment
failure of the intervention [35]. Recent studies show
that CQ withdrawal from use for a number of years has
reversed resistance based on prevalence of Pfcrt re-
sistance marker [36,37]. This was possible since CQ
use was totally banned making its availability to both
health facilities and local drug vendors difficult. A
survey done in 2007 documented CQ use in Tanzania
at 0.5% and in Malawi at 0.8% [38]. This led to the
reported recovery of CQ susceptibility in Tanzania and
Malawi. Conversely, due to continued use of SP for
IPTp, SP is readily available in both public and the pri-
vate sector making its restriction to only IPTp impos-
sible. In the current situation it is unlikely that self-
medication with SP can be prevented especially due to
its low cost compared to ACT, which may also explain
the observed high prevalence of SP resistance markers
despite its replacement with ACT. Use of SP-artesunatecombination is also another selection factor for SP-
resistance markers, however, in Tanzania SP-AS is not
used instead artemether-lumefantrine (ALu) is the
approved ACT. Furthermore, it is expected as the quin-
tuple mutation continues to rise towards fixation, the
Pfdhps 581G mutation considered to confer SP super-
resistance when in combination with the 540E will con-
tinue to rise. It is important for the responsible author-
ities to consider restricting SP to IPTp only, through
restricting its general prescription and its availability to
local drug vendors. An alternative drug for IPTp is
urgently needed.
Conclusion
In this study prevalence of SP resistance based on quin-
tuple mutations in Tanzania is high, approaching fix-
ation levels. This trend has been observed in other
parts of East Africa. The spread of SP super-resistance
is expected with continued SP use and may lead to poor
SP-IPTp outcome despite continued recommendation
by the WHO. An urgent search for alternative drugs
for IPTp in East Africa is required.
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